Drug Profile
Vafidemstat - Oryzon Genomics
Alternative Names: ORY-2001Latest Information Update: 05 Mar 2024
Price :
$50
*
At a glance
- Originator Oryzon
- Developer Institute of Medical and Molecular Genetics; Oryzon
- Class Amines; Antidementias; Antiparkinsonians; Antipsychotics; Behavioural disorder therapies; Cyclopropanes; Neuroprotectants; Nootropics; Oxadiazoles; Small molecules
- Mechanism of Action Lysine specific demethylase 1 inhibitors; Monoamine oxidase B inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Phase II Aggression; Alzheimer's disease; Borderline personality disorders; Multiple sclerosis; SARS-CoV-2 acute respiratory disease; Schizophrenia
- Preclinical Autistic disorder
- No development reported Dementia; Huntington's disease; Parkinson's disease; Telomeric 22q13 Monosomy Syndrome
Most Recent Events
- 05 Mar 2024 Oryzon Genomics plans a registrational phase III trial for Borderline personality disorder
- 26 Feb 2024 Oryzon Genomics announces intention to request an End-of phase II meeting with the US FDA for a registrational phase III trial in Borderline personality disorder
- 28 Jan 2024 No recent reports of development identified for clinical-Phase-Unknown development in Telomeric-22q13-Monosomy-Syndrome in Europe (PO)